Differential Response to Sorafenib Administration for Advanced Hepatocellular Carcinoma

Differential Response to Sorafenib Administration for Advanced Hepatocellular Carcinoma

Sorafenib has been used to treat advanced hepatocellular carcinoma (aHCC). However, there is no evidence for a response of different target lesions to sorafenib administration. Therefore, we aimed to evaluate the effect of sorafenib on various aHCC target lesions. The outcomes of sorafenib treatment...

Full description

Bibliographic Details
Main Authors: Song-Fong Huang, Sio-Wai Chong, Chun-Wei Huang, Heng-Yuan Hsu, Kuang-Tse Pan, Chien-Fu Hung, Tsung-Han Wu, Chao-Wei Lee, Chia-Hsun Hsieh, Ching-Ting Wang, Pei-Mei Chai, Ming-Chin Yu
Format: Article
Language:English
Published: MDPI AG 2022-09-01
Series:Biomedicines
Subjects:
advanced HCC
sorafenib
target lesions
ALBI
Online Access:https://www.mdpi.com/2227-9059/10/9/2277

Internet

https://www.mdpi.com/2227-9059/10/9/2277

Similar Items